Merck & Co has reached an agreement to buy Prometheus Biosciences in a $200-per-share ... PRA023 had the potential to be a “pipeline in a product”. Meanwhile, following after PRA023 is PRA052 ...

Merck, of Rahway, N.J., had sold some ophthalmology drugs, but it abandoned the market about a decade ago, divesting itself of the remaining products ... Prometheus Biosciences last year and ...

The company has made moves in the oncology space in recent years, including an October 2024 acquisition of Modifi Biosciences ... up to $1.3bn. Merck KGaA’s top-selling product in 2024 was ...